Skip to main content
OpenTrials
Completed

NCT Number: NCT03355781

Childhood Trauma in Schizophrenia: Exploration of Links Between Gene Expression, Cerebral Morphology and Symptomatology

Childhood trauma is known as a vulnerability factor in schizophrenia. In healthy volunteers, these adversities are linked to a decrease of grey matter of the brain, similar to those observed in schizophrenia.

In a previous study based on Voxel-Based Morphometry (VBM), including 21 schizophrenic patients and 30 healthy volunteers, the investigators shown a negative correlation between emotional neglect (important dimension in childhood trauma) and grey matter decrease. This strong correlation was significantly higher in schizophrenic patients than in healthy volunteers, suggesting a higher genetic predisposition to environmental factors in schizophrenic people.

Currently, interaction between genetic predisposition and environmental stress factors is the major model for understanding in schizophrenia. In order to analyze both effects on human body, particularly on brain, several studies currently focus on the product of genetic expression, the ribonucleic acid (ARN).

The purpose of this study is to provide an explanatory model of links between childhood trauma, candidate gene for schizophrenia expression, cerebral morphology and schizophrenic symptomatology. Using conceptual framework of stress vulnerability, structural equation modeling (SEM) will allow testing causal link between these different variables.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Saint Etienne

Saint-Etienne, 42055, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

of patients :

  • For women with reproductively active age period: suitable contraceptive method and negative pregnancy test
  • Schizophrenia diagnosis (according to DSM 5)
  • Regular follow-up care at hospital
  • No change in antipsychotic medication (medication AND dosage) within at least six weeks
  • Patient into remission : constant dosage, out-patient and meeting Andreassen criteria
  • Who have given their informed consent before participating in the study.
  • Physical examination without significant clinical physical anomaly
  • No serious somatic pathology
  • Affiliates or entitled to a social security scheme

Exclusion criteria

of patients :

  • For women with reproductively active age period: no suitable contraceptive method (oral, hormonal, intramuscular, intrauterine device, or surgical)
  • Pregnancy or breastfeeding
  • Not meeting schizophrenic criteria according to DSM 5 or presenting resistant schizophrenic criteria according Kane criteria
  • Presenting a serious somatic disorder or neurological (particularly Parkinson disease, epilepsy, tardive dyskinesia)
  • Cardiovascular, hepatic or serious renal diseases
  • Contraindication to MRI examination, particularly ocular or intracranial metallic foreign object,pacemaker, artificial heart valve, surgical clip
  • Claustrophobia, significant tatoo in the high part of the body, IUD incompatible with MRI 3Tesla
  • Alcohol or drug addiction, within the last year
  • Recruited in other clinical trial or exclusion period from previous trial.
  • Susceptibility to self-harm behaviour according to investigator

Inclusion criteria

of Related volunteers :

  • Age, gender and socio-educational level similar to recruited patients
  • Who have given their informed consent before participating in the study.
  • First degree relative of schizophrenic patient diagnosed according DSM IV criteria
  • No schizophrenia diagnosis according DSM IV criteria
  • No psychiatric history and free of psychotropic drugs/treatment
  • Physical examination without significant clinical anomaly
  • Affiliates or entitled to a social security scheme

Exclusion criteria

of Related volunteers :

  • For women with reproductively active age period: no suitable contraceptive method (oral, hormonal, intramuscular, intrauterine device, or surgical)
  • Pregnancy or breastfeeding
  • Presenting somatic, neurological or psychiatric disorder
  • Alcohol or drug addiction, within the last year
  • Recruited in other clinical trial or exclusion period from previous trial.
  • Contraindication to MRI examination, particularly ocular or intracranial metallic foreign object, pacemaker, artificial heart valve, surgical clip
  • Claustrophobia, significant tatoo in the high part of the body, IUD incompatible with MRI 3Tesla

Inclusion criteria

of Healthy volunteers :

  • Age, gender and socio-educational level similar to recruited patients
  • Who have given their informed consent before participating in the study.
  • No schizophrenia diagnosis according DSM IV criteria
  • No personal or family history of psychiatric disorders
  • Free of psychotropic drugs/treatment
  • Physical examination without significant clinical anomaly
  • Affiliates or entitled to a social security scheme

Exclusion criteria

of Healthy volunteers :

Beside the absence of schizophrenia diagnosis, healthy volunteers should meet the same exclusion criteria as patients

Treatment and study plan

Magnetic Resonance Imaging (MRI)

Device

brain imaging : structural anatomy, emotional congruence, anatomic connectivity, functional connectivity

Blood sample

Procedure

27,5 ml of blood sample : genetic analysis and biobank

Clinical psychiatric evaluation

Other

Global Assessment Scale(GAS),Mini International Neuropsychiatric Interview(MINI),Positive and Negative Symptoms Scale(PANSS),Family Interview for Genetic Studies(FIGS),Calgary Depression Scale for Schizophrenia(CDSS),extrapyramidal side effects evaluation or Simpson-Angus scale evaluation(ESRS),Apathy Evaluation Scale(AES-C),State-Trait Anxiety Inventory(STAI),Beck Depression Inventory(BDI-13),Eysenck Personality Questionnaire-Revised(EPQ-R),Assessment of Schizotypal Personality(SPQ),Emotion Regulation Questionnaire(ERQ),Emotional Reactivity Scale(ERS),Toronto Alexithymia Scale(TAS-20),social anhedonia scale(SAS),Childhood Trauma Questionnaire(CTQ),Clinical-administered Post Traumatic Stress Disorder Scale(CAPS),Wechsler Adult Intelligence Scale(WAIS-III),Trail Making Test(TMT),Pen and paper visuospatial working memory(DOT-test),impulsivity test(GoStop),Stroop test,National Adult Reading Test(NART),Wechsler Adult Intelligence Scale(WAIS-III),Facial Emotion Recognition task(FER)

Primary outcomes

  1. Childhood Trauma Questionnaire (CTQ) for childhood trauma.

    Time frame: 5 days

    development of an etiopathogenic model characteristic of schizophrenia

    Childhood Trauma Questionnaire : to assess five types of childhood trauma :

    • Emotional neglect
    • physical abuse
    • emotional abuse
    • physical neglect
    • sexual abuse

    Each item being rated in 5 answer choice from 1 to 5 (never, rarely, sometimes, often or very often)

  2. Quantitative measurement of RNAs

    Time frame: 5 days

    development of an etiopathogenic model characteristic of schizophrenia

  3. Voxel-based morphometry (VBM) for total gray matter

    Time frame: 5 days

    development of an etiopathogenic model characteristic of schizophrenia

  4. Voxel-based morphometry (VBM) for regional gray matter density.

    Time frame: 5 days

    development of an etiopathogenic model characteristic of schizophrenia

Secondary outcomes

  1. Connectivity in the cortico-limbic circuit

    Time frame: 5 days

  2. Volumetry of the brain

    Time frame: 5 days

  3. Correlation of BOLD activity in the cortico-limbic circuit in patients with patients with symptomatic variables

    Time frame: 5 days

    symptomatic variables : PANSS scale

  4. Correlation of BOLD activity in the cortico-limbic circuit with emotional variables

    Time frame: 5 days

    emotional variables : ERS scale, ERQ scale, TAS-20 scale, SAS scale, AES-C scale

  5. Correlation of BOLD activity in the cortico-limbic circuit with personality characteristics

    Time frame: 5 days

    personality characteristics : EPQ-R scale, SPQ scale

  6. Correlation of BOLD activity in the cortico-limbic circuit with history of trauma in childhood

    Time frame: 5 days

    history of trauma in childhood : CTQ scale

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Saint Etienne

Other

Registry information

Official study title

Childhood Trauma in Schizophrenia: Exploration of Links Between Gene Expression, Cerebral Morphology and Symptomatology. SCHIZO' TRAUMA

Acronym: SCHIZO'TRAUMA

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Nov 28, 2017
Registry last updated
Jan 17, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.